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Figure 1. (A) Equilibrium and (B) Dynamic modulus of cultured explants
over 6 weeks – All replicates of all donors combined
Figure 2. (A) GAG in explants and (B) GAG released in media
Figure 3. (A) MMP activity in media and (B) Collagen content in explants.
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examination, KSS and KOOS evaluation. Another 371 knees completed
the subjective outcome evaluation by telephone questionnaires. Of the
505 knees available for ﬁnal review the subjective assessment was
satisfactory in 432 (85.5%). For the 134 knees received in-depth out-
come studies, the Knee Society scores and all subscales of KOOS
improved statistically. The FTA improved from 1.57 (SD 3.9) to 1.93 (SD
4.1) (p¼0.03) and the JSW increased from 3.02 (SD 1.24) to 3.17 (SD 1.17)
(p¼0.01). The radiographic outcome revealed reversal of the degener-
ation process over the medial compartment in 82.1% of these knees
(N¼134).
Conclusion: Based on these translational investigations, we conclude
that MAS might be a cause of OA knee and can be effectively treated by
AMR.
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SPRIFERMIN (RHFGF18) PRESERVES ARTICULAR CARTILAGE
PROPERTIES DURING IN VITRO CULTURE
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Purpose: Current clinical practice of osteochondral allograft trans-
plantation requires time delay between tissue harvest and trans-
plantation for testing of bacterial and viral contamination. Allografts
are stored in cold conditions to preserve viability and tissue proper-
ties. Although not ideal, due to low chondrocyte survival, this proce-
dure is preferred to in vitro culture, as the latter results in rapid loss of
mechanical properties and GAG content. More generally, in vitro
culture of explants is used experimentally to study chondrocyte
response in their natural environment; however rapid turnover of
matrix makes results stemming from long-term cultures difﬁcult to
interpret. Several studies focused on developing in vitro culture sys-
tems to preserve allograft native properties, including a report of a
serum-free media formulation containing dexamethasone that pre-
served mechanical properties and biochemical content in juvenile
bovine explants for up to 8 weeks. Sprifermin (recombinant human
FGF18 (rhFGF18)) stimulates chondrocyte proliferation and matrix
production in vitro, reduces cartilage degeneration and increases de
novo matrix formation by osteoarthritic cartilage in vivo. In this study,
we evaluated the potential of Sprifermin to preserve explant proper-
ties in serum-containing media.
Methods: Full thickness cartilage explants (4mm diameter) were
harvested from trochlear grooves of juvenile bovine knees. After
overnight culture in complete medium, explants were trimmed to
similar thickness and cultured in complete medium with or
without rhFGF18 (Sprifermin, 100 ng/ml) applied for 24 hours
each week (1þ6 treatment). Over 6 weeks, explant mechanical
properties and molecular aspects were evaluated. Explants were
tested in unconﬁned compression to determine equilibrium (10%
strain, stress relaxation) and dynamic (1% strain, 1Hz) com-
pressive properties. For each explant, GAG content was deter-
mined using DMMB assay. Media was harvested at each media
change, and GAG release and MMP activity evaluated using DMMB
assay and SensoLyte 520 Generic MMP assay kit (Anaspec),
respectively.
Results: Mechanical integrity of cartilage explants cultured in vitro
decreases 1 week after isolation (EY¼1285 at Day0, 975 at Wk1), sta-
bilizing by week 2 at w 40% of original level (Fig 1A and 1B). This
phenomenon may relate in part to loss of proteoglycan from cut sur-
faces. When explants were cultured in serum-containing media with
Sprifermin, properties were preserved during week 1 of culture. After
week 1, treated and untreated explants decreased in properties, with
treated samples higher than untreated samples through week 3
(Untreated: EY¼563, G*¼7797 at Wk3; Treated: EY¼751, G*¼11287 at
Wk3).
By 4 weeks, no statistical differences were seen between treated and
untreated groups. At week 6, treated samples had lower EY but same G*
as untreated explantsThese differences could not solely be explained by GAG content (Fig 2A),
which showed continual decrease over time, with no statistical differ-
ences between treated and untreated explants until week 6, where
there was less GAG in treated explants (1.12% vs. 2.38%).At weeks 2 and 3, GAG release to the media was higher in treated
explants (Fig 2B), whereas MMP activity in treated explants was lower
(Fig 3A; Wk2: 0.87 mM vs. 0.10 mM; Wk3: 0.53 mM vs. 0.13 mM).MMP activity levels, collagen content of treated explants was higher
than untreated explants, with statistically signiﬁcant difference at week
3 (6.72% vs. 3.61% respectively), which could explain higher mechanical
properties of treated explants throughweek 3 (Fig 1A). This suppression
of MMP activity by rhFGF18 dissipated after week 4, both groups having
the same level of MMP activity.
Conclusions: Taken together, our results showed Sprifermin has an
inhibitory effect on MMP activity, which suppressed for 3 weeks deg-
radation of explant collagen. This study illustrates the potential of
Sprifermin to preserve cartilage explant mechanical properties over a
clinically relevant time course during which testing occurs before
allograft implantation. Hence current practice of storing allografts in
the cold could be replaced by maintenance of important cartilage
properties in the presence of rhFGF18 during the time period required
for safety screening.
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NOVEL TECHNIQUE TO MAP THE BIOMECHANICAL PROPERTIES OF
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